Regulators have cleared Sanofi-Aventis' $1.9 billion purchase of Gold Bond skin products maker Chattem Inc., the French drugmaker said Tuesday. Sanofi-Aventis said a mandatory Federal Trade Commission review period has ended. The company agreed to buy Chattem in December for $93 ...

LONDON (Reuters) - A "silent pandemic" of chronic disease is creeping up on poor countries and will force pharmaceutical firms to take a more tiered approach to pricing some of their most lucrative medicines. Drugs for diseases which were previously dominant only in the rich, well-fed world, such as diabetes, heart disease and cancer, are increasingly in demand in poorer nations ...

Drug developer Vical Inc. said Monday the Agriculture Department approved Oncept, a vaccine intended to treat oral melanoma in dogs. Vical developed the drug and licensed it to Merial Ltd., a division of French drugmaker Sanofi-Aventis. It said Merial plans to launch Oncept at the North American ...

Drug developer Sanofi-Aventis said Friday it named Hans Regenauer vice president of consumer health care in Europe and of global development. He joins the company from Boehringer Ingelheim where he served as senior vice president of consumer health care. Shares of Sanofi-Aventis, based in Paris, fell 26 ...